Legend Biotech Corporation
LEGN
$34.18
-$0.52-1.50%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 120.66% | 174.02% | 229.60% | 165.07% | 95.69% |
| Total Other Revenue | 1,740.61% | 1,458.18% | 903.49% | -77.43% | -63.09% |
| Total Revenue | 122.96% | 176.93% | 231.84% | 163.30% | 94.50% |
| Cost of Revenue | 23.55% | 23.53% | 27.65% | 31.34% | 65.61% |
| Gross Profit | 66.09% | 55.89% | 35.00% | 17.51% | -46.05% |
| SG&A Expenses | 37.94% | 26.76% | 20.35% | 15.44% | -0.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.58% | 24.42% | 25.53% | 26.53% | 18.72% |
| Operating Income | 21.90% | 25.61% | 15.70% | 5.22% | 1.24% |
| Income Before Tax | 32.13% | 45.97% | 10.97% | -14.39% | -24.98% |
| Income Tax Expenses | 844.17% | -383.68% | -436.78% | -503.46% | -8.41% |
| Earnings from Continuing Operations | 31.65% | 46.43% | 11.44% | -13.87% | -24.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.65% | 46.43% | 11.44% | -13.87% | -24.95% |
| EBIT | 21.90% | 25.61% | 15.70% | 5.22% | 1.24% |
| EBITDA | 22.48% | 26.22% | 16.07% | 5.45% | 1.24% |
| EPS Basic | 35.97% | 50.45% | 20.47% | -3.20% | -12.85% |
| Normalized Basic EPS | 36.50% | 50.07% | 20.14% | -3.74% | -13.05% |
| EPS Diluted | 36.04% | 50.49% | 20.37% | -3.43% | -13.05% |
| Normalized Diluted EPS | 36.50% | 50.07% | 20.14% | -3.74% | -13.05% |
| Average Basic Shares Outstanding | 6.21% | 9.08% | 11.38% | 10.66% | 11.24% |
| Average Diluted Shares Outstanding | 6.21% | 9.08% | 11.38% | 10.66% | 11.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
